IDEAS home Printed from https://ideas.repec.org/d/ohecouk.html
 

Publications

by members of

Office of Health Economics
London, United Kingdom

These are publications listed in RePEc written by members of the above institution who are registered with the RePEc Author Service. Thus this compiles the works all those currently affiliated with this institution, not those affilated at the time of publication. List of registered members. Register yourself. Citation analysis. This page is updated in the first days of each month.
| Working papers | Journal articles | Books |

Working papers

2023

  1. Chris Sampson;Edward Oliver;Priscila Radu;Tanja Podkonjak;Lotte Steuten, 2023. "The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe," Contract Research 002468, Office of Health Economics.

2022

  1. Adrian Towse & Rachel Silverman Bonnifield, 2022. "An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment," Policy Papers 277, Center for Global Development.
  2. Dimitrios Kourouklis & Mikel Berdud & Mireia Jofre-Bonet & Adrian Towse, 2022. "Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases," Post-Print hal-03710938, HAL.

2021

  1. David Mott;Gayathri Kumar;Chris Sampson;Martina Garau, 2021. "How is Quality of Life Measured for Health Technology Assessments?," Briefing 002357, Office of Health Economics.

2020

  1. Chris Sampson;David Parkin;Nancy Devlin, 2020. "Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?," Grant-Funded Research 002308, Office of Health Economics.

2019

  1. Chris Sampson;Martina Garau, 2019. "How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy," Briefing 002146, Office of Health Economics.
  2. Amanda Cole;Adrian Towse;Bernarda Zamora, 2019. "Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?," Briefing 002176, Office of Health Economics.
  3. Amanda Cole;Adrian Towse;Bernarda Zamora, 2019. "Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?," Briefing 002165, Office of Health Economics.
  4. Mikel Berdud & Kalipso Chalkidou & Emma Dean & Jimena Ferraro & Lou Garrison & Cassandra Nemzoff & Adrian Towse, 2019. "The Future of Global Health Procurement: Issues around Pricing Transparency," Working Papers 507, Center for Global Development.

2018

  1. Paula Lorgelly;Amanda Cole;Phill O’Neill;Chris Sampson, 2018. "Barriers to Uptake of Minimal Access Surgery in the United Kingdom," Contract Research 001976, Office of Health Economics.
  2. Chris Sampson;Phill O’Neill;Paula Lorgelly, 2018. "The Impact of New Medicines in the NHS: 70 Years of Innovation," Contract Research 002047, Office of Health Economics.
  3. Mikel Berdud;Martina Garau;Margherita Neri;Phill O’Neill;Chris Sampson;Adrian Towse, 2018. "R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C," Grant-Funded Research 002040, Office of Health Economics.
  4. Jofre-Bonet, Mireia & Kamara, Joseph, 2018. "Willingness to pay for health insurance in the informal sector of Sierra Leone," LSE Research Online Documents on Economics 89836, London School of Economics and Political Science, LSE Library.
  5. Margherita Neri;Adrian Towse;Martina Garau, 2018. "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefing 002084, Office of Health Economics.

2017

  1. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
  2. Margherita Neri;Adrian Towse, 2017. "Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?," Briefing 001922, Office of Health Economics.

2016

  1. Amanda Cole;Grace Hampson;Nancy Devlin;David Grainger;Eui-Kyung Lee;Wija Oortwijn, 2016. "“New Age” Decision Making in HTA: Is It Applicable in Asia?," Briefing 001741, Office of Health Economics.
  2. Joan Costa-i-Font & Mireia Jofre-Bonet, 2016. "Like Mother, Like Father? Gender Assortative Transmission of Child Overweight," CESifo Working Paper Series 5985, CESifo.
  3. Amanda Cole;Adrian Towse;Michelle Mujoomdar;Arnold Chan;Franz Pichler, 2016. "How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?," Briefing 001740, Office of Health Economics.

2015

  1. Joan Costa-i-Font & Mireia Jofre-Bonet & Julian Le Grand, 2015. "Vertical Transmission of Overweight: Evidence from English Adoptees," CESifo Working Paper Series 5351, CESifo.
  2. Sarah Karlsberg-Schaffer;Jon Sussex;Yan Feng, 2015. "Incentives to follow Best Practice in Health Care," Briefing 001583, Office of Health Economics.
  3. Jorge Mestre-Ferrandiz;Renato Dellamano;Michele Pistollato;Adrian Towse, 2015. "Multi-indication Pricing: Pros, Cons and Applicability to the UK," Seminar Briefing 001653, Office of Health Economics.

2014

  1. Jofre-Bonet, Mireia & Pesendorfer, Martin, 2014. "Optimal sequential auctions," LSE Research Online Documents on Economics 56438, London School of Economics and Political Science, LSE Library.
  2. Adrian Towse, 2014. "Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?," Occasional Paper 001561, Office of Health Economics.
  3. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014. "Motivational Capital and Incentives in Health Care Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1403, Departamento de Economía - Universidad Pública de Navarra.
  4. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014. "A Pilot Inquiry on Incentives and Intrinsic Motivation in Health Care: the Motivational Capital Explained by Doctors," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1401, Departamento de Economía - Universidad Pública de Navarra.

2013

  1. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.
  2. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.
  3. Sampson, Christopher & James, Marilyn & Huband, Nick & Geelan, Steve & McMurran, Mary, 2013. "Cost implications of treatment non-completion in a forensic personality disorder service," MPRA Paper 48757, University Library of Munich, Germany.
  4. Hernández-Alava, Mónica & Sampson, Christopher & Wailoo, Allan, 2013. "Happy and healthy: a joint model of health and life satisfaction," MPRA Paper 49766, University Library of Munich, Germany.
  5. Sampson, Christopher & James, Marilyn & Whynes, David, 2013. "The relationship between individual risk and cost-effectiveness in screening interventions," MPRA Paper 51799, University Library of Munich, Germany.
  6. Joan Costa-i-Font & Mireia Jofre-Bonet, 2013. "In brief...Eating disorders: the impact of self-image and peer pressure," CentrePiece - The magazine for economic performance 406, Centre for Economic Performance, LSE.
  7. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper 000106, Office of Health Economics.

2012

  1. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & Andrew Street, 2012. "Analysing Hospital Variation in Health Outcome at the Level of EQ-5D Dimensions," Working Papers 074cherp, Centre for Health Economics, University of York.
  2. Versteegh, MM & Attema, AE & Oppe, M & Devlin, NJ & Stolk, EA, 2012. "Time to tweak the TTO. But how?," MPRA Paper 37989, University Library of Munich, Germany.
  3. Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz, 2012. "Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context," NBER Working Papers 18593, National Bureau of Economic Research, Inc.
  4. Lou Garrison;Ruth Puig-Peiro;Adrian Towse, 2012. "The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?," Occasional Paper 000167, Office of Health Economics.
  5. Mikel Berdud & Juan M. Cabasés & Jorge Nieto, 2012. "Incentives Beyond the Money: Identity and Motivational Capital in Public Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1214, Departamento de Economía - Universidad Pública de Navarra.
  6. Mikel Berdud & Juan M. Cabasés Hita, 2012. "Incentives Beyond the Money and Motivational Capital in Health Care Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1201, Departamento de Economía - Universidad Pública de Navarra.

2011

  1. Cubí-Mollá Patricia & Herrero Carmen, 2011. "Quality of Life Lost Due to Non-Fatal Road Crashes," Working Papers 2011104, Fundacion BBVA / BBVA Foundation.
  2. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & David Parkin & Andrew Street, 2011. "Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes," Working Papers 068cherp, Centre for Health Economics, University of York.
  3. Joan Costa Font & Mireia Jofre-Bonet, 2011. "Anorexia, Body Image and Peer Effects: Evidence from a Sample of European Women," CEP Discussion Papers dp1098, Centre for Economic Performance, LSE.
  4. Joan Costa-i-Font & Mireia Jofre-Bonet & Steven T. Yen, 2011. "Not All Incentives Wash Out the Warm Glow: The Case of Blood Donation Revisited," CESifo Working Paper Series 3527, CESifo.
  5. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2011. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement," NBER Working Papers 17174, National Bureau of Economic Research, Inc.
  6. Patricia Danzon;Martina Garau;Adrian Towse, 2011. "Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?," Occasional Paper 000191, Office of Health Economics.

2010

  1. Patricia Cubí Mollá, 2010. "Scaling methods for categorical self-assessed health measures," Working Papers. Serie AD 2010-01, Instituto Valenciano de Investigaciones Económicas, S.A. (Ivie).
  2. Priya Sharma;Adrian Towse, 2010. "New Drugs to Tackle Antimicrobial Resistance: EU Policy Options," Occasional Paper 000216, Office of Health Economics.

2009

  1. Devlin, N. & Parkin, D. & Browne, J., 2009. "Using the EQ-5D as a performance measurement tool in the NHS," Working Papers 09/03, Department of Economics, City University London.
  2. Costa-Font, Joan & Jofre-Bonet, Mireia, 2009. "Body image, peer effects and food disorders: evidence from a sample of European women," LSE Research Online Documents on Economics 27751, London School of Economics and Political Science, LSE Library.
  3. Jorge Mestre-Ferrandiz;Martina Garau, 2009. "Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries," Briefing 000227, Office of Health Economics.

2008

  1. Parkin, D. & Rice, N. & Devlin, N., 2008. "Statistical analysis of EQ-5D profiles: does the use of value sets bias inference?," Working Papers 08/10, Department of Economics, City University London.
  2. Joan Costa i Font & Mireia Jofre-Bonet, 2008. "Body image and food disorders: Evidence from a sample of European women," Working Papers 2008-30, FEDEA.
  3. Albert Banal-Estañol & Mireia Jofre-Bonet & Cornelia Meissner, 2008. "Theimpact of industry collaboration on research: Evidence from engineering academics in the UK," Economics Working Papers 1190, Department of Economics and Business, Universitat Pompeu Fabra, revised Aug 2010.
  4. Deven Chauhan;Jorge Mestre-Ferrandiz;Adrian Towse, 2008. "The Market for Biosimilars: Evolution and Policy Options," Briefing 000238, Office of Health Economics.

2006

  1. Dimakou, S. & Parkin, D. & Devlin, N. & Appleby, J., 2006. "The impact of government targets on waiting times for elective surgery: new insights from time-to-event analysis," Working Papers 06/05, Department of Economics, City University London.
  2. Martin Buxton;Adrian Towse, 2006. "Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds," Briefing 000267, Office of Health Economics.
  3. Conradie, Beatrice & Cookson, Graham & Thirtle, Colin G., 2006. "Efficiency and Pooling in Western Cape Wine Grape Production," 2006 Annual Meeting, August 12-18, 2006, Queensland, Australia 25522, International Association of Agricultural Economists.

2005

  1. Sadique, Z. & Edmunds, W. J. & Devlin, N. & Parkin, D., 2005. "Understanding individuals’ decisions about vaccination: a comparison between Expected Utility and Regret Theory models," Working Papers 05/03, Department of Economics, City University London.

2004

  1. Parkin, D. & Devlin, N., 2004. "Is there a case for using Visual Analogue Scale valuations in Cost-Utility Analysis?," Working Papers 04/03, Department of Economics, City University London.
  2. Susan H. Busch & Mireia Jofre-Bonet & Tracy A. Falba & Jody L. Sindelar, 2004. "Tobacco Spending and its Crowd-Out of Other Goods," NBER Working Papers 10974, National Bureau of Economic Research, Inc.

2003

  1. Paul Fenn;Alastair Gray;Neil Rickman;Rodrigo Salinas;Adrian Towse, 2003. "Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?," Briefing 000484, Office of Health Economics.

2002

  1. Tsuchiya, A & Brazier, J & McColl, E & Parkin, D, 2002. "Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices," MPRA Paper 29740, University Library of Munich, Germany.
  2. Mireia Jofre-Bonet & Jody L. Sindelar, 2002. "Drug Treatment as a Crime Fighting Tool," NBER Working Papers 9038, National Bureau of Economic Research, Inc.

2001

  1. Mireia Jofre-Bonet & Martin Pesendorfer, 2001. "Estimation of a Dynamic Auction Game," NBER Working Papers 8626, National Bureau of Economic Research, Inc.

2000

  1. Kobelt, Gisela & Lindgren, Peter & Parkin, David & Francis, David A. & Johnson, Michael & Bates, David & Jönsson, Bengt, 2000. "Costs and Quality of Life in Multiple Sclerosis. A Cross-Sectional Observational Study in the UK," SSE/EFI Working Paper Series in Economics and Finance 398, Stockholm School of Economics.
  2. Nancy Devlin & Paul Hansen, 2000. "Allocating Vote: Health — ‘Needs Assessment’ and an Economics-Based Approach," Treasury Working Paper Series 00/04, New Zealand Treasury.
  3. N J Devlin & P Hansen & P Kind & A H Williams, 2000. "The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs," Working Papers 180chedp, Centre for Health Economics, University of York.

1998

  1. Michael F. Drummond;Adrian Towse, 1998. "From Efficacy to Cost-Effectiveness," Briefing 000438, Office of Health Economics.

1997

  1. Martin Cave;Adrian Towse, 1997. "Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry," Briefing 000427, Office of Health Economics.

1970

  1. Martina Garau, 1970. "Estimating Pharmaceutical Companies' Value to the Nation: Case Study of the British Pharma Group," Briefing 000245, Office of Health Economics.

Journal articles

2023

  1. Brassel, Simon & Al Taie, Amer & Steuten, Lotte, 2023. "Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?," Health Policy, Elsevier, vol. 136(C).

2022

  1. Cate Bailey & Kim Dalziel & Paula Cronin & Nancy Devlin & Rosalie Viney, 2022. "How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents," PharmacoEconomics, Springer, vol. 40(2), pages 157-182, February.
  2. Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & , 2022. "Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures," PharmacoEconomics, Springer, vol. 40(4), pages 379-431, April.
  3. Cate Bailey & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Elisabeth Huynh & Emily Lancsar & Brendan J. Mulhern & Richard Nor, 2022. "Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review," PharmacoEconomics, Springer, vol. 40(7), pages 663-698, July.
  4. Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & , 2022. "Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures," PharmacoEconomics, Springer, vol. 40(4), pages 477-478, April.
  5. Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin, 2022. "A Comparison of PROPr and EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 40(3), pages 297-307, March.
  6. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
  7. Chris Sampson, 2022. "NICE and the EQ-5D-5L: Ten Years Trouble," PharmacoEconomics - Open, Springer, vol. 6(1), pages 5-8, January.

2021

  1. Amira El-Shal & Patricia Cubi-Molla & Mireia Jofre-Bonet, 2021. "Accreditation as a quality-improving policy tool: family planning, maternal health, and child health in Egypt," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 115-139, February.
  2. Patricia Cubi-Molla & Martin Buxton & Nancy Devlin, 2021. "Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 635-644, September.
  3. Andrew J. Palmer & Julie A. Campbell & Barbara de Graaff & Nancy Devlin & Hasnat Ahmad & Philip M Clarke & Mingsheng Chen & Lei Si, 2021. "Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1950-1977, August.
  4. David J. Mott & Koonal K. Shah & Juan Manuel Ramos-Goñi & Nancy J. Devlin & Oliver Rivero-Arias, 2021. "Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?," Medical Decision Making, , vol. 41(5), pages 584-596, July.
  5. Tessa Peasgood & Clara Mukuria & Jill Carlton & Janice Connell & Nancy Devlin & Karen Jones & Rosemary Lovett & Bhash Naidoo & Stacey Rand & Juan Carlos Rejon-Parrilla & Donna Rowen & Aki Tsuchiya & J, 2021. "What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the dev," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(7), pages 1067-1081, September.
  6. Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin, 2021. "EQ-5D-5L Health-State Values for the Mexican Population," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 905-914, November.
  7. Richard De Abreu Lourenço & Nancy Devlin & Kirsten Howard & Jason J. Ong & Julie Ratcliffe & Jo Watson & Esther Willing & Elisabeth Huynh, 2021. "Giving a Voice to Marginalised Groups for Health Care Decision Making," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 14(1), pages 5-10, January.
  8. Chris Sampson & Isobel Firth & Adrian Towse, 2021. "Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al," Medical Decision Making, , vol. 41(3), pages 255-257, April.
  9. Kyann Zhang & Gayathri Kumar & Chris Skedgel, 2021. "Towards a New Understanding of Unmet Medical Need," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 785-788, November.

2020

  1. Paula Lorgelly & Jack Pollard & Patricia Cubi-Molla & Amanda Cole & Duncan Sim & Jon Sussex, 2020. "Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 13(5), pages 599-610, October.
  2. Nils Gutacker & Thomas Patton & Koonal Shah & David Parkin, 2020. "Using EQ-5D Data to Measure Hospital Performance: Are General Population Values Distorting Patients’ Choices?," Medical Decision Making, , vol. 40(4), pages 511-521, May.
  3. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
  4. Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe, 2020. "Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?," PharmacoEconomics, Springer, vol. 38(4), pages 325-340, April.
  5. Juan M. Ramos-Goñi & Mark Oppe & Elly Stolk & Koonal Shah & Simone Kreimeier & Oliver Rivero-Arias & Nancy Devlin, 2020. "International Valuation Protocol for the EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 38(7), pages 653-663, July.
  6. Zhang, Angela & Prang, Khic-Houy & Devlin, Nancy & Scott, Anthony & Kelaher, Margaret, 2020. "The impact of price transparency on consumers and providers: A scoping review," Health Policy, Elsevier, vol. 124(8), pages 819-825.
  7. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.
  8. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020. "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, vol. 124(6), pages 639-646.
  9. David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins, 2020. "A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 69-79, February.
  10. David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins, 2020. "Authors’ Reply to Hays: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance”," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 459-460, June.

2019

  1. Pickles, Kristen & Lancsar, Emily & Seymour, Janelle & Parkin, David & Donaldson, Cam & Carter, Stacy M., 2019. "Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study," Social Science & Medicine, Elsevier, vol. 240(C).
  2. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
  3. Fan Yang & Nancy Devlin & Nan Luo, 2019. "Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 99-105, February.
  4. Nancy J. Devlin, 2019. "All Male Panels and Other Diversity Considerations for ISPOR," PharmacoEconomics - Open, Springer, vol. 3(3), pages 423-426, September.
  5. Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward , 2019. "Transparency in Decision Modelling: What, Why, Who and How?," PharmacoEconomics, Springer, vol. 37(11), pages 1355-1369, November.
  6. Bengt Jönsson & Grace Hampson & Jonathan Michaels & Adrian Towse & J.-Matthias Graf Schulenburg & Olivier Wong, 2019. "Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 427-438, April.

2018

  1. Patricia Cubi-Molla & Koonal Shah & Kristina Burström, 2018. "Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(3), pages 253-270, June.
  2. Yan Feng & Nancy J. Devlin & Koonal K. Shah & Brendan Mulhern & Ben van Hout, 2018. "New methods for modelling EQ‐5D‐5L value sets: An application to English data," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 23-38, January.
  3. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
  4. Amanda Cole & Koonal Shah & Brendan Mulhern & Yan Feng & Nancy Devlin, 2018. "Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 595-605, May.
  5. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018. "3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, vol. 36(6), pages 637-640, June.
  6. Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill, 2018. "Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(11), pages 1345-1353, November.
  7. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.
  8. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018. "Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 36(6), pages 727-727, June.
  9. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018. "Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 36(6), pages 699-713, June.
  10. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018. "Correction to: 3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, vol. 36(6), pages 729-729, June.
  11. Camilleri, Carl & Jofre-Bonet, Mireia & Serra-Sastre, Victoria, 2018. "The suitability of a DRG casemix system in the Maltese hospital setting," Health Policy, Elsevier, vol. 122(11), pages 1183-1189.
  12. Jofre-Bonet, Mireia & Serra-Sastre, Victoria & Vandoros, Sotiris, 2018. "The impact of the Great Recession on health-related risk factors, behaviour and outcomes in England," Social Science & Medicine, Elsevier, vol. 197(C), pages 213-225.
  13. Gerard Harty & James Jarrett & Mireia Jofre-Bonet, 2018. "Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work," Applied Health Economics and Health Policy, Springer, vol. 16(4), pages 515-525, August.
  14. Graham Cookson & Ioannis Laliotis, 2018. "Promoting normal birth and reducing caesarean section rates: An evaluation of the Rapid Improvement Programme," Health Economics, John Wiley & Sons, Ltd., vol. 27(4), pages 675-689, April.

2017

  1. Patricia Cubí‐Mollá & Mireia Jofre‐Bonet & Victoria Serra‐Sastre, 2017. "Adaptation to health states: Sick yet better off?," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1826-1843, December.
  2. Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard, 2017. "Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 967-977, November.
  3. Mike Herdman & Jameel Nazir & Zalmai Hakimi & Emad Siddiqui & Moses Huang & Marco Pavesi & Scott MacDiarmid & Marcus J. Drake & Nancy Devlin, 2017. "Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 10(6), pages 677-686, December.
  4. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017. "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 469-477, August.
  5. Nancy J. Devlin & Richard Brooks, 2017. "EQ-5D and the EuroQol Group: Past, Present and Future," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 127-137, April.
  6. Christopher James Sampson & Tim Wrightson, 2017. "Model Registration: A Call to Action," PharmacoEconomics - Open, Springer, vol. 1(2), pages 73-77, June.
  7. Towse, Adrian & Hoyle, Christopher K. & Goodall, Jonathan & Hirsch, Mark & Mestre-Ferrandiz, Jorge & Rex, John H., 2017. "Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation," Health Policy, Elsevier, vol. 121(10), pages 1025-1030.
  8. Yan Feng & Toby Watt & Anita Charlesworth & Grace Marsden & Adam Roberts & Jon Sussex, 2017. "What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation," Applied Economics and Finance, Redfame publishing, vol. 4(6), pages 1-16, November.
  9. Graham Cookson & Simon Jones & Ioannis Laliotis, 2017. "Cancelled Procedures in the English NHS: Evidence from the 2010 Tariff Reform," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 126-139, December.

2016

  1. David Parkin & Nancy Devlin & Yan Feng, 2016. "What Determines the Shape of an EQ-5D Index Distribution?," Medical Decision Making, , vol. 36(8), pages 941-951, November.
  2. Mikel Berdud & Adrian Towse & Hannah Kettler, 2016. "Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 32(1), pages 64-87.
  3. Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016. "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, vol. 34(6), pages 609-616, June.

2015

  1. David Nuttall & David Parkin & Nancy Devlin, 2015. "Inter‐Provider Comparison Of Patient‐Reported Outcomes: Developing An Adjustment To Account For Differences In Patient Case Mix," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 41-54, January.
  2. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
  3. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015. "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, vol. 119(9), pages 1237-1244.
  4. Feng Xie & A. Pickard & Paul Krabbe & Dennis Revicki & Rosalie Viney & Nancy Devlin & David Feeny, 2015. "A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)," PharmacoEconomics, Springer, vol. 33(8), pages 867-877, August.
  5. Banal-Estañol, Albert & Jofre-Bonet, Mireia & Lawson, Cornelia, 2015. "The double-edged sword of industry collaboration: Evidence from engineering academics in the UK," Research Policy, Elsevier, vol. 44(6), pages 1160-1175.
  6. Sarah Karlsberg Schaffer, 2015. "The Effect of Free Personal Care for the Elderly on Informal Caregiving," Health Economics, John Wiley & Sons, Ltd., vol. 24(S1), pages 104-117, March.
  7. Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison, 2015. "European Union Pharmaceutical Markets: A Case for Differential Pricing?," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 263-275, July.
  8. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
  9. Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, March.

2014

  1. Jofre-Bonet, Mireia & Pesendorfer, Martin, 2014. "Optimal sequential auctions," International Journal of Industrial Organization, Elsevier, vol. 33(C), pages 61-71.
  2. Michael Drummond & Adrian Towse, 2014. "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 335-340, May.
  3. A. Chapman & C. Taylor & A. Girling, 2014. "Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP)," Applied Health Economics and Health Policy, Springer, vol. 12(4), pages 347-357, August.
  4. Blanc-Brude, Frédéric & Cookson, Graham & Piesse, Jenifer & Strange, Roger, 2014. "The FDI location decision: Distance and the effects of spatial dependence," International Business Review, Elsevier, vol. 23(4), pages 797-810.

2013

  1. Md Z Sadique & Nancy Devlin & William J Edmunds & David Parkin, 2013. "The Effect of Perceived Risks on the Demand for Vaccination: Results from a Discrete Choice Experiment," PLOS ONE, Public Library of Science, vol. 8(2), pages 1-9, February.
  2. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy J. Devlin & David Parkin & Andrew Street, 2013. "Truly Inefficient Or Providing Better Quality Of Care? Analysing The Relationship Between Risk‐Adjusted Hospital Costs And Patients' Health Outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 22(8), pages 931-947, August.
  3. Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.
  4. Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk, 2013. "Time to tweak the TTO: results from a comparison of alternative specifications of the TTO," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 43-51, July.
  5. Nancy Devlin & Paul Krabbe, 2013. "The development of new research methods for the valuation of EQ-5D-5L," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 1-3, July.
  6. Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin, 2013. "Lead versus lag-time trade-off variants: does it make any difference?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 25-31, July.
  7. Nancy Devlin & Ken Buckingham & Koonal Shah & Aki Tsuchiya & Carl Tilling & Grahame Wilkinson & Ben van Hout, 2013. "A Comparison Of Alternative Variants Of The Lead And Lag Time Tto," Health Economics, John Wiley & Sons, Ltd., vol. 22(5), pages 517-532, May.
  8. Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin, 2013. "The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 15-24, July.
  9. Koonal Shah & Andrew Lloyd & Mark Oppe & Nancy Devlin, 2013. "One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 65-73, July.
  10. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & Andrew Street, 2013. "Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions," Medical Decision Making, , vol. 33(6), pages 804-818, August.
  11. Christopher Sampson & David Whitehurst & Andrew Street, 2013. "Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 703-705, August.
  12. Joan Costa-Font & Mireia Jofre-Bonet, 2013. "Anorexia, Body Image and Peer Effects: Evidence from a Sample of European Women," Economica, London School of Economics and Political Science, vol. 80(317), pages 44-64, January.
  13. Joan Costa-Font & Mireia Jofre-Bonet & Steven T. Yen, 2013. "Not All Incentives Wash Out the Warm Glow: The Case of Blood Donation Revisited," Kyklos, Wiley Blackwell, vol. 66(4), pages 529-551, November.
  14. Graham Cookson & Simon Jones & Bryan McIntosh, 2013. "Cancelled Procedures: Inequality, Inequity And The National Health Service Reforms," Health Economics, John Wiley & Sons, Ltd., vol. 22(7), pages 870-876, July.

2012

  1. Patricia Cubí‐Mollá & Carmen Herrero, 2012. "Quality of life lost due to non‐fatal road traffic injuries," Health Economics, John Wiley & Sons, Ltd., vol. 21(5), pages 528-550, May.
  2. Michael Drummond & Adrian Towse, 2012. "Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 1-5, February.

2011

  1. Nancy J. Devlin & Aki Tsuchiya & Ken Buckingham & Carl Tilling, 2011. "A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach," Health Economics, John Wiley & Sons, Ltd., vol. 20(3), pages 348-361, March.
  2. Adrian Towse & Priya Sharma, 2011. "Incentives for R&D for New Antimicrobial Drugs," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 331-350.

2010

  1. David Parkin & Nigel Rice & Nancy Devlin, 2010. "Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?," Medical Decision Making, , vol. 30(5), pages 556-565, September.
  2. Nancy J. Devlin & David Parkin & John Browne, 2010. "Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 886-905, August.
  3. Phill O’Neill & Nancy Devlin, 2010. "An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions," PharmacoEconomics, Springer, vol. 28(11), pages 987-993, November.
  4. Carl Tilling & Nancy Devlin & Aki Tsuchiya & Ken Buckingham, 2010. "Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review," Medical Decision Making, , vol. 30(5), pages 610-619, September.

2009

  1. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.
  2. Sofia Dimakou & David Parkin & Nancy Devlin & John Appleby, 2009. "Identifying the impact of government targets on waiting times in the NHS," Health Care Management Science, Springer, vol. 12(1), pages 1-10, March.
  3. Buckingham, Ken J. & Devlin, Nancy Joy, 2009. "A note on the nature of utility in time and health and implications for cost utility analysis," Social Science & Medicine, Elsevier, vol. 68(2), pages 362-367, January.

2008

  1. Jofre-Bonet, Mireia & Petry, Nancy M., 2008. "Trading apples for oranges?: Results of an experiment on the effects of Heroin and Cocaine price changes on addicts' polydrug use," Journal of Economic Behavior & Organization, Elsevier, vol. 66(2), pages 281-311, May.
  2. Joan Costa‐Font & Mireia Jofre‐Bonet, 2008. "Is There A ‘Secession Of The Wealthy’? Private Health Insurance Uptake And National Health System Support," Bulletin of Economic Research, Wiley Blackwell, vol. 60(3), pages 265-287, July.

2007

  1. David Parkin & Nancy Devlin, 2007. "‘Is there a case for using visual analogue scale valuations in CUA? Yes there is a case, but what does it add to ordinal data?’ a rejoinder," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 649-651, June.

2006

  1. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.
  2. Ken Buckingham & Nancy Devlin, 2006. "A theoretical framework for TTO valuations of health," Health Economics, John Wiley & Sons, Ltd., vol. 15(10), pages 1149-1154, October.
  3. Dakin, Helen Angela & Devlin, Nancy J. & Odeyemi, Isaac A.O., 2006. ""Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making," Health Policy, Elsevier, vol. 77(3), pages 352-367, August.
  4. Joan Costa-Font & Mireia Jofre-Bonet, 2006. "Are Private Health Insurance Subscribers Unsatisfied with the Spanish National Health System?," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan;The Geneva Association, vol. 31(4), pages 650-668, October.
  5. Michael Drummond & Anne Mason & Adrian Towse, 2006. "The desirability and feasibility of economic studies of drugs post-launch," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 5-6, March.
  6. Beatrice Conradie & Graham Cookson & Colin Thirtle, 2006. "Efficiency And Farm Size In Western Cape Grape Production: Pooling Small Datasets," South African Journal of Economics, Economic Society of South Africa, vol. 74(2), pages 334-343, June.

2005

  1. Ashton, Toni & Mays, Nicholas & Devlin, Nancy, 2005. "Continuity through change: The rhetoric and reality of health reform in New Zealand," Social Science & Medicine, Elsevier, vol. 61(2), pages 253-262, July.
  2. Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran, 2005. "A ‘new and improved’ EQ-5D valuation questionnaire?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 73-82, March.

2004

  1. Parkin, David & Rice, Nigel & Jacoby, Ann & Doughty, Julie, 2004. "Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life," Social Science & Medicine, Elsevier, vol. 59(2), pages 351-360, July.
  2. Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.
  3. Nancy J. Devlin, 2004. "Getting Health Economics into Practice, Edited by David Kernick. Radcliffe Medical Press, Oxford, 2002. No. of pages: 358. ISBN 1‐85775‐575‐8," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 499-500, May.
  4. Diego Ossa & Adrian Towse, 2004. "Genetic screening, health care and the insurance industry," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 116-121, May.

2003

  1. Wolfgang Greiner & Tom Weijnen & Martin Nieuwenhuizen & Siem Oppe & Xavier Badia & Jan Busschbach & Martin Buxton & Paul Dolan & Paul Kind & Paul Krabbe & Arto Ohinmaa & David Parkin & Montserat Roset, 2003. "A single European currency for EQ-5D health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 222-231, September.
  2. Nancy J. Devlin & Paul Hansen & Paul Kind & Alan Williams, 2003. "Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffs," Health Economics, John Wiley & Sons, Ltd., vol. 12(7), pages 529-544, July.
  3. Mireia Jofre-Bonet & Martin Pesendorfer, 2003. "Estimation of a Dynamic Auction Game," Econometrica, Econometric Society, vol. 71(5), pages 1443-1489, September.

2002

  1. Angela Robinson & David Parkin, 2002. "Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. A response to Sculpher and Gafni," Health Economics, John Wiley & Sons, Ltd., vol. 11(7), pages 649-651, October.
  2. Nancy J. Devlin, 2002. "The Purchasing of Health Care by Primary Care Organisations. An evaluation and Guide to Future Policy, by N. Mays, S. Wyke, G. Malbon, N. Goodwin. Open University Press, Buckingham and Philadelphia, 2," Health Economics, John Wiley & Sons, Ltd., vol. 11(6), pages 567-568, September.

2001

  1. Nancy Devlin & Paul Hansen, 2001. "Health care spending and economic output: Granger causality," Applied Economics Letters, Taylor & Francis Journals, vol. 8(8), pages 561-564.

2000

  1. Jofre-Bonet, Mireia & Pesendorfer, Martin, 2000. "Bidding behavior in a repeated procurement auction: A summary," European Economic Review, Elsevier, vol. 44(4-6), pages 1006-1020, May.
  2. Jofre-Bonet, Mireia, 2000. "Health care: private and/or public provision," European Journal of Political Economy, Elsevier, vol. 16(3), pages 469-489, September.
  3. Mireia Jofre-Bonet, 2000. "Public health care and private insurance demand: The waiting time as a link," Health Care Management Science, Springer, vol. 3(1), pages 51-71, January.

1999

  1. David Parkin & Nigel Rice & Matthew Sutton, 1999. "Non‐ and semi‐parametric estimation of age and time heterogeneity in repeated cross‐sections: an application to self‐reported morbidity and general practitioner utilization1," Health Economics, John Wiley & Sons, Ltd., vol. 8(5), pages 429-440, August.
  2. Scuffham, P. & Devlin, N. & Eberhart-Phillips, J. & Wilson-Salt, R., 1999. "The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule," Social Science & Medicine, Elsevier, vol. 49(6), pages 763-779, September.
  3. Mason, Anne & Drummond, Michael & Towse, Adrian, 1999. "Is disease management relevant in Europe: some evidence from the United Kingdom," Health Policy, Elsevier, vol. 48(1), pages 69-77, July.
  4. Adrian Towse & Patricia Danzon, 1999. "Medical negligence and the NHS: an economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 8(2), pages 93-101, March.

1997

  1. Miller, Paul & Parkin, David & Craig, Neil & Lewis, David & Gerard, Karen, 1997. "Less fog on the Tyne? Programme budgeting in Newcastle and North Tyneside," Health Policy, Elsevier, vol. 40(3), pages 217-229, June.
  2. David Parkin & Bruce Hollingsworth, 1997. "Measuring production efficiency of acute hospitals in Scotland, 1991-94: validity issues in data envelopment analysis," Applied Economics, Taylor & Francis Journals, vol. 29(11), pages 1425-1433.

1996

  1. Szeto, Kam Leong & Devlin, Nancy J., 1996. "The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand," Health Policy, Elsevier, vol. 38(2), pages 101-115, November.

1995

  1. Craig, Neil & Parkin, David & Gerard, Karen, 1995. "Clearing the fog on the Tyne: programme budgeting in Newcastle and North Tyneside Health Authority," Health Policy, Elsevier, vol. 33(2), pages 107-125, August.
  2. Anthony Scott & David Parkin, 1995. "Investigating hospital efficiency in the new NHS: The role of the translog cost function," Health Economics, John Wiley & Sons, Ltd., vol. 4(6), pages 467-478, November.
  3. Nancy Devlin & Paul Hansen & Stephen Knowles, 1995. "Comment: Financing New Zealand’s Tertiary Education: How Much Subsidy?," Agenda - A Journal of Policy Analysis and Reform, Australian National University, College of Business and Economics, School of Economics, vol. 2(2), pages 223-225.

1994

  1. Devlin, N.J., 1994. "The effects of denturism: New Zealand dentists' response to competition," American Journal of Public Health, American Public Health Association, vol. 84(10), pages 1675-1677.
  2. Adrian Towse, 1994. "The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8," Health Economics, John Wiley & Sons, Ltd., vol. 3(5), pages 347-348, September.

1991

  1. Bryan, Stirling & Parkin, David & Donaldson, Cam, 1991. "Chiropody and the QALY: a case study in assigning categories of disability and distress to patients," Health Policy, Elsevier, vol. 18(2), pages 169-185, July.

1989

  1. Parkin, David, 1989. "Comparing Health Service Efficiency Across Countries," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 5(1), pages 75-88, Spring.

1987

  1. Parkin, David & McGuire, Alistair & Yule, Brian, 1987. "Aggregate health care expenditures and national income : Is health care a luxury good?," Journal of Health Economics, Elsevier, vol. 6(2), pages 109-127, June.

1985

  1. Yule, Brian & Parkin, David, 1985. "The demand for dental care: An assessment," Social Science & Medicine, Elsevier, vol. 21(7), pages 753-760, January.

Books

2014

  1. Wren, Maev-Ann & Gillespie, Paddy & Smith, Samantha & Kearns, Karen & Crichton,Siobhan & Parkin, David & Hickey, Anne & Horgan, Frances & Wiley, Miriam, 2014. "Towards Earlier Discharge, Better Outcomes, Lower Cost: Stroke Rehabilitation in Ireland," Research Series, Economic and Social Research Institute (ESRI), number BKMNEXT277, June.

2012

  1. Jorge Mestre-Ferrandiz;Jon Sussex;Adrian Towse, 2012. "The R&D Cost of a New Medicine," Monograph 000135, Office of Health Economics.

2011

  1. Nancy Devlin;Jon Sussex, 2011. "Incorporating Multiple Criteria in HTA: Methods and Processes," Monograph 000189, Office of Health Economics.
  2. Priya Sharma;Adrian Towse, 2011. "New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options," Monograph 000184, Office of Health Economics.

2010

  1. Nancy Devlin;John Appleby, 2010. "Getting the Most out of PROMs: Putting Health Outcomes at the Heart of NHS Decision-Making," Monograph 000220, Office of Health Economics.
  2. Adrian Towse;Nancy Mattison;Jorge Mestre-Ferrandiz, 2010. "Biosimilars: How Much Entry and Price Competition Will Result?," Monograph 000195, Office of Health Economics.
  3. Phill O’Neill, 2010. "Shedding the Pounds: Obesity Management, NICE Guidance and Bariatric Surgery in England," Monograph 000204, Office of Health Economics.

2006

  1. Anne R. Mason;Michael F. Drummond;Adrian Towse, 2006. "Economic Post-Launch Studies: Matching the Desirable with the Feasible," Monograph 000268, Office of Health Economics.

2004

  1. John Appleby;Nancy Devlin;Diane Dawson, 2004. "How Much Should We Spend on the NHS?," Monograph 000490, Office of Health Economics.

2002

  1. Clive Pritchard;Nancy Devlin;Adrian Towse, 2002. "Cost-Effectiveness Thresholds: Economic and ethical issues," Monograph 000473, Office of Health Economics.
  2. Anne R. Mason;Michael F. Drummond;Jonathan Cooke;Adrian Towse, 2002. "Influencing Prescribing in a Primary Care Led NHS," Monograph 000476, Office of Health Economics.
  3. Hannah Kettler;Adrian Towse, 2002. "Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty," Monograph 000479, Office of Health Economics.

1999

  1. Anne R. Mason;Michael F. Drummond;Adrian Towse, 1999. "Disease Management, the NHS and the Pharmaceutical Industry," Monograph 000446, Office of Health Economics.

1997

  1. Adrian Towse, 1997. "Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?," Monograph 000423, Office of Health Economics.

1995

  1. Adrian Towse, 1995. "Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS," Monograph 000409, Office of Health Economics.
  2. Adrian Towse, 1995. "Industrial Policy and the Pharmaceutical Industry," Monograph 000414, Office of Health Economics.
  3. David Hale;Adrian Towse, 1995. "Value of the Pharmaceutical Industry to the UK Economy," Monograph 000415, Office of Health Economics.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.